Drugs used in hypoplastic, haemolytic and renal anaemias (Formulary)

TAM (Treatments and Medicines) NHS Highland
NHS Highland

DARBEPOETIN ALFA - (First line)

Therapy notes

  • All patients on darbepoetin will have their treatment prescribed, supplied and monitored by their clinical speciality. 
  • For renal patients contact the anaemia co-ordinator for supply.

Formulation and dosage details

Formulation:

Injection (Aranesp®) pre-filled syringes 10 micrograms/0·4mL, 15 micrograms/0·375mL, 20 micrograms/0·5mL, 30 micrograms/0·3mL, 40 micrograms/0·4mL, 50 micrograms/0·5mL, 60 micrograms/0·3mL, 80 micrograms/0·4mL, 100 micrograms/0·5mL, 130 micrograms/0·65mL, 150 micrograms/0·3mL, 300 micrograms/0·6mL (s)

Dosage:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Formulation and dosage details

Formulation:

Injection (Aranesp® SureClick) pre-filled disposable injection device 20 micrograms/0·5mL, 40 micrograms/0·4mL, 60 micrograms/0·3mL, 80 micrograms/0·4mL, 100 micrograms/0·5mL, 150 micrograms/0·3mL (s)

Dosage:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

EPOETIN BETA

Therapy notes

MHRA advice: Epoetin beta (NeoRecormon) increased risk of retinopathy in preterm infants cannot be excluded (May 2015) (www.gov.uk).

  • Reco-Pen® injection devices and needles are available from Raigmore Hospital pharmacy.

Formulation and dosage details

Formulation:

Injection (NeoRecormon®) pre-filled syringe 2,000 units, 3,000 units, 4,000 units, 6,000 units, 10,000 units, 20,000 units (s)

ROXADUSTAT

Therapy notes

Formulation and dosage details

Formulation:

Tablets 20mg, 50mg, 70mg, 100mg, 150mg (Restricted: hospital use only)

Dosage:

SMC2461: Treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).
SMC restriction: for use in patients who are non-dialysis dependent (NDD) at the time of treatment initiation

Guideline: Anaemia in chronic kidney disease

Editorial Information

Document Id: F287